We are live on
!
Find out more
RCM
RA Capital Management Portfolio holdings
AUM
$9.44B
1-Year Est. Return
157.3%
This Fund
S&P 500
This Quarter
Est. Return
+48.92%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$7.15B
AUM Growth
+$1.69B
(+31%)
Cap. Flow
+$592M
Cap. Flow
% of AUM
8.27%
Top 10 Holdings %
Top 10 Hldgs %
50.83%
Holding
92
New
22
Increased
4
Reduced
19
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Novavax
NVAX
|
+$275M |
| 2 |
Atea Pharmaceuticals
AVIR
|
+$173M |
| 3 |
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
|
+$144M |
| 4 |
Olema Pharmaceuticals
OLMA
|
+$101M |
| 5 |
Rocket Pharmaceuticals
RCKT
|
+$77.9M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Seres Therapeutics
MCRB
|
+$134M |
| 2 |
EIDX
Eidos Therapeutics, Inc. Common Stock
EIDX
|
+$109M |
| 3 |
Vaxcyte
PCVX
|
+$58.5M |
| 4 |
VXRT
Vaxart
VXRT
|
+$51.3M |
| 5 |
ADAP
Adaptimmune Therapeutics
ADAP
|
+$48M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 93.77% |
| 2 | Financials | 0.3% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ascendis Pharma A/S
ASND
$16.6B
| $978M | 13.67% |
5,865,338
-44,404
| -0.8% | -$7.34M |
|
2
TG Therapeutics
TGTX
$8.38B
| $452M | 6.32% |
8,685,471
-140,378
| -2% | -$4.74M |
|
|
3
Novavax
NVAX
$1.22B
| $422M | 5.91% |
3,788,564
+2,589,962
| +216% | +$275M |
|
4
Nkarta
NKTX
$154M
| $345M | 4.82% |
5,605,129
| – | – |
|
|
FMTX
5
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $315M | 4.4% |
9,011,651
| – | – |
|
6
Arvinas
ARVN
$534M
| $312M | 4.36% |
3,672,872
| – | – |
|
|
CCXI
7
DELISTED
ChemoCentryx, Inc.
CCXI
| $296M | 4.13% |
4,776,548
-50,362
| -1% | -$2.88M |
|
|
8
Atea Pharmaceuticals
AVIR
$367M
| $224M | 3.14% |
+5,368,451
| New | +$173M |
|
|
ITOS
9
DELISTED
iTeos Therapeutics
ITOS
| $149M | 2.09% |
4,417,258
| – | – |
|
|
KNTE
10
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $143M | 2% |
+3,593,052
| New | +$144M |
|
11
Axsome Therapeutics
AXSM
$11.8B
| $135M | 1.89% |
1,655,447
-379,685
| -19% | -$28.4M |
|
12
Keros Therapeutics
KROS
$199M
| $132M | 1.85% |
1,875,000
| – | – |
|
13
Phathom Pharmaceuticals
PHAT
$944M
| $127M | 1.78% |
3,825,008
| – | – |
|
14
Rhythm Pharmaceuticals
RYTM
$7.41B
| $124M | 1.74% |
4,179,067
-961,341
| -19% | -$24.4M |
|
15
Travere Therapeutics
TVTX
$5.29B
| $124M | 1.74% |
4,557,867
-77,820
| -2% | -$1.82M |
|
|
IMGN
16
DELISTED
Immunogen Inc
IMGN
| $119M | 1.66% |
18,417,458
+11,376,973
| +162% | +$66.4M |
|
|
17
Rocket Pharmaceuticals
RCKT
$342M
| $117M | 1.64% |
+2,136,081
| New | +$77.9M |
|
|
ETNB
18
DELISTED
89bio
ETNB
| $115M | 1.61% |
4,736,214
| – | – |
|
|
ZGNX
19
DELISTED
Zogenix, Inc.
ZGNX
| $107M | 1.49% |
5,345,631
-142,793
| -3% | -$2.92M |
|
20
PMV Pharmaceuticals
PMVP
$57.6M
| $105M | 1.47% |
1,710,265
| – | – |
|
|
21
Olema Pharmaceuticals
OLMA
$998M
| $103M | 1.45% |
+2,150,404
| New | +$101M |
|
|
ADVM
22
DELISTED
Adverum Biotechnologies
ADVM
| $103M | 1.44% |
950,238
+9,152
| +1% | +$1.13M |
|
23
MacroGenics
MGNX
$238M
| $100M | 1.4% |
4,375,217
| – | – |
|
|
24
Vaxcyte
PCVX
$7.7B
| $98.6M | 1.38% |
3,710,699
-1,573,119
| -30% | -$58.5M |
|
|
IGMS
25
DELISTED
IGM Biosciences
IGMS
| $86.8M | 1.21% |
982,723
| – | – |
|
Similar funds
RCMNY
SCM
SIM
NPT
AC
PVI
WPL
BAMF
RA Capital Management's Q4 2020 Portfolio in Review
As of Q4 2020, RA Capital Management held 92 positions worth $7.15B, up 31% from $5.47B the previous quarter. Its ten largest holdings account for 51% of the portfolio.
RA Capital Management deployed $592M of net new capital in Q4 2020, opening 22 new positions and adding to 4 existing holdings. Its largest new stake was Atea Pharmaceuticals: 5,368,451 shares worth $224M.
By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 93% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Vaxcyte, an estimated $58.5M trimmed.
- RA Capital Management's largest Q4 2020 buy was Atea Pharmaceuticals: 5,368,451 shares worth $224M.
- RA Capital Management added most to Novavax in Q4 2020, an estimated $275M increase.
- RA Capital Management's biggest Q4 2020 reduction was Vaxcyte, cutting an estimated $58.5M.
- RA Capital Management fully exited Seres Therapeutics in Q4 2020, selling an estimated $134M.
- RA Capital Management's ten largest holdings make up 51% of its $7.15B portfolio in Q4 2020.
- RA Capital Management opened 22 new positions and closed 10 in Q4 2020.
- RA Capital Management's portfolio value rose 31% quarter-over-quarter to $7.15B.
Based on RA Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.